Can Invokana Do A Januvia In India?
This article was originally published in PharmAsia News
Invokana has all the attributes to be a winner, to go by comments from Janssen India, but achieving success for the new diabetes brand will hinge on pricing, deft marketing and wide acceptance from medical practitioners. Ace marketing executive and chief of the subsidiary’s pharma business, Sanjiv Navangul, apparently also plans to deepen access to the drug in India through other new approaches.
You may also be interested in...
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.